This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Exploring Nasal Casts in Nasal Drug Development
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Delivering Nasally Administered Biologics
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions
Nasal Casts, Tools to Enable Nasal Drug Delivery Development
Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Optimizing Preclinical Studies for Intranasal and Pulmonary Programs
Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights
